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Manganese is a vital nutrient and is maintained at an optimal level (2.5–5mg/day) in human body. Chronic exposure to manganese
is associated with neurotoxicity and correlated with the development of various neurological disorders such as Parkinson’s disease.
Oxidative stressmediated apoptotic cell death has been well establishedmechanism inmanganese induced toxicity. Oxidative stress
has a potential to alter the epigenetic mechanism of gene regulation. Epigenetic insight of manganese neurotoxicity in context of
its correlation with the development of parkinsonism is poorly understood. Parkinson’s disease is characterized by the 𝛼-synuclein
aggregation in the form of Lewy bodies in neuronal cells. Recent findings illustrate that manganese can cause overexpression of
𝛼-synuclein. 𝛼-Synuclein acts epigenetically via interaction with histone proteins in regulating apoptosis. 𝛼-Synuclein also causes
global DNA hypomethylation through sequestration of DNA methyltransferase in cytoplasm. An individual genetic difference
may also have an influence on epigenetic susceptibility to manganese neurotoxicity and the development of Parkinson’s disease.
This review presents the current state of findings in relation to role of epigenetic mechanism in manganese induced neurotoxicity,
with a special emphasis on the development of Parkinson’s disease.
1. Introduction
Manganese (Mn) is an essential trace element maintained
at an optimal level in human body for proper functioning
of brain. Manganese also plays significant role in carbohy-
drate, lipid, and protein metabolism and acts as a cofactor
for various antioxidant enzymes like superoxide dismutase,
glutamine synthetase, and so forth [1]. Chronic exposure to
manganese is known to induce neurotoxicity [2]. Most of the
epidemiological studies on exposure to manganese pertain to
its effect on occupational workers. High environment level of
manganese may be a potential risk factor in causing disorder
associatedwith developing nervous system aswell as for adult
brain [3, 4]. Welders and miners are the diverse occupational
population who are exposed to manganese. Manganese,
through inhalation, enters the body circulation and affects
the central nervous system [5]. The neurological disorders
similar to schizophrenia and Parkinson’s disease (PD) have
been observed to be due to excessive manganese intake from
both environment and occupational settings characterized
by dopaminergic cell death [6, 7]. Occupational exposure of
manganese at an elevated level may cause manganism with
neurological symptoms resembling idiopathic Parkinson’s
disease (IPD) [8]. Settivari’s study showed the probable
genetic linkage between manganism and idiopathic Parkin-
son’s disease (IPD) [8]. This suggests the common molecular
modalities involved in pathophysiology of both disorders.
However the identification of key molecular determinants
largely remains elusive. This prolonged exposure has been
associated with increased risk for PD [9, 10]. Initiation of
oxidative stress resulting from discrepancy between ROS
and antioxidant generation is considered to be the probable
mechanism of neurotoxicity as manganese can initiate apop-
tosis and/or necrotic cell death in neuronal or glial cells [11–
13].
Dynamic chromatin remodeling governs the accessibility
of transcription factors to promoters regions of genes, thereby
regulating gene expression [14]. Epigenetic mechanisms such
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as DNA methylation, histone modification, and microRNAs
participate in regulating the gene expression. A growing
number of evidences suggest that exposure to environmental
toxicants may induce alterations in gene expression through
epigenetic mechanisms that can be linked to disease suscep-
tibility and development. Epigenetic deregulation may lead
to the development of neurological disorders like Parkinson’s
disease, Huntington’s disease, and mood disorders (depres-
sion and anxiety) [15]. Millions of people worldwide are
affected by the most common movement disorder known as
Parkinson’s disease (PD). Apart from mutation in genome,
various environmental and occupational factors such as
pesticides like paraquat and metals such as manganese have
been considered as risk factor for the development of Parkin-
son’s disease [16]. Parkinson’s disease is characterized by the
presence of 𝛼-synuclein proteinaceous inclusions, known as
Lewy bodies (LBs) and Lewy neurites (LNs) in the dopamin-
ergic neurons of brain. 𝛼-Synuclein aggregation in neuronal
cells in form of Lewy bodies is a pathological hallmark of
Parkinson’s disease. Manganese has been found to accelerate
the 𝛼-synuclein aggregation in neuronal cell line by inducing
the overexpression of 𝛼-synuclein [17]. The significance of
elevated 𝛼-synuclein expression can be understood by the
fact that 50% increase in 𝛼-synuclein expression has been
hypothesized to cause Parkinson’s disease [18]. ROS have the
potential to influence epigenetic processes through oxidative
stress mechanism [19].
The review is an effort to generate the working hypothesis
based on the present knowledge of mechanism underlying
themanganese exposure, parkinsonism, and epigeneticmod-
ifications over genetic susceptibility.There are many assump-
tions suggested, lacking epigenetic studies on manganese
exposure. It is also an attempt to link the possible role of
epigenetic mechanism in implication of Parkinson’s disease
induced by manganese. The hypothesis indicated in this
review may be relevant and needed consideration in future
studies.
2. Manganese in Environment and
Its Route of Exposure
Even though manganese is required in trace amount, expo-
sure from both environmental and occupational settings has
been reported to be toxic for brain and central nervous
system (CNS). During each life stage the increased exposure
to manganese may occur with different absorption routes.
Hence lifetime exposure to manganese is important in
considering its toxicological aspect [20]. Table 1 depicts the
major sources and route of manganese exposure. Relative
potential for exposure depends on the sources of exposure.
For example, intake due to inhalation of ambient air has
higher risk potential compared to that of the ingestion of
manganese from diet, drinking water, and so forth.
Manganese is common constituent of ground water.
Elevated level of manganese may exist because of certain
bedrock formation (geogenic) or anthropogenic activities
[21]. Common population could be exposed to high level of
manganese through consumption of well/drinking water or
inhalation of atmospheric air with manganese released as a
combustion product of methylcyclopentadienyl manganese
tricarbonyl (MMT) (a petrol antiknock additive) [21–23].
Exposure to manganese through contaminated drinking
water that exceeds theWHO regulatory standards (400 𝜇g/L)
has been associated with adverse neurological problems [24,
25]. Manganese exposure through water rather than diet has
been associated with significant deposition of manganese in
hair samples of children [26]. Manganese has been found
in breast milk of population residing near to industrial steel
plant [27]. As a nutritional supplement, manganese is added
to a variety of foods such as soy containing infant formulas.
The highest concentration of manganese has been reported
in herbal food including grain, rice, nuts, and tea [28–
30]. Manganese-containing pesticides maneb and paraquat
have been used to treat various plant pathologies [31]. An
epidemiological observation has reported an increased risk
of developing Parkinson’s disease in rural area population
exposed to these pesticides [31–33]. Elevated intake above a
recommended level may be a concern in dietary foods for
general population. Neurotoxicity of manganese varies with
its route of exposure. Toxicity of manganese is least among
all other toxic trace metals when uptake is via ingestion com-
pared to its exposure through inhalation (Table 1). Inhaled
manganese provides a direct path to brain tissue through
olfactory neural pathway (nasal airways) while lung uptake
has long residence time with continuous source of exposure.
The intake of manganese via inhalation rather than ingestion
is a major concern as it is evident that inhaled manganese
enters the body circulation and can be directly transported to
the central nervous system [34].Manganese is found at higher
level in ambient air near industries engaged with processing
or use of manganese. To increase the strength and stiffness,
manganese is used in the steelmaking industries. The miners
andworkers of ferroalloy, smelting, andmetallurgy industries
along with battery and car machine manufactures are the
heterogeneous populationwho are occupationally exposed to
respirable metal dust particles [35–37]. The Unified Parkin-
son’s Disease Rating Motor Scale 3 (UPDRS3) was used for
accessing the risk of parkinsonism in welding fumes exposed
workers. The results of the study depict significant difference
in the UPDRS3 scale of welding exposed and nonwelder
reference subjects [38].This signifies the association between
welding fume exposure and parkinsonism. Positron emission
tomography and radiotracer FDOPA based investigation of
weldingworkerswithmild parkinsonism sign have shown the
evidence of dopaminergic dysfunction in the caudate nucleus
[39]. This strengthens the evidence for neurotoxic effects of
welding fumes.
Epidemiological observation and studies show that man-
ganism and parkinsonism are the two manifestations of
manganese exposure. These neurodegenerative manifesta-
tions may stand at two extreme conditions depending on the
intensity, duration, and route of exposure [40]. Manganism
is the result of high acute exposure whereas parkinsonism
happens due to low chronic exposure. According to the
WHO, manganism can occur when the airborne concentra-
tion of manganese in inhalable particles is above 1mg/m3
while parkinsonism may result from lifetime exposure to
much lower concentration of around 100 ng/m3 ofmanganese
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Table 1: The table shows the major sources and routes of manganese exposure along with their relative potential for exposure to population.
Route of exposure Source of exposure Basis for exposure Relative potential for exposure
Ingestion
Diet Manganese in breast milk, infant formula,and leafy vegetables, fruit, and fruit juices
Relatively lower for general
population but higher prenatal
and infant exposure
Ground water
Drinking water
Surface water
As a natural constituent of water but
elevated level may present at some water
source because of pollution sources or
bedrock formation
Lower
Soil Manganese may present in soil but not amajor contributor to exposure Lower
Inhalation
Ambient air
Higher air concentration nearby
industries (mining operations, metal
processing plants, etc.) (MMT as additive
in gasoline) is cause of concern for
residential population
Higher
Indoor air
Significantly lower but associated with
Mn in outdoor dust and the distance
from industrial point sources
Relatively lower but implication
for childhood exposure
in respirable dust particles [35, 41–43]. The delayed and
long term toxicity may result due to cumulative exposure to
manganese along with other known neurotoxicants such as
pesticide and lead. Brain may be unable to compensate the
exposure tomultiple neurotoxicants leading to persistent and
cumulative damage [44]. Thus, lifetime chronic exposure to
manganese from prenatal to oldermay be considered as a risk
factor for development of parkinsonism [42]. Morphological,
neurochemical, and behavioral alterations were reported in
rat exposed to MnCl
2
/Mn(OAc)
3
through inhalation route.
These alterations were similar to those observed in PD [45].
Entering the brain, manganese gets accumulated in several
regions particularly in globus pallidus, substantia nigra pars
compacta, and other ganglia structures [46]. Manganism
appears due to accumulation of manganese specifically
in globus pallidus region of brain, whereas parkinsonism
results from accumulation in other brain regions including
globus pallidus and substantia nigra as depicted in Figure 1.
Although globus pallidus is major site of Mn deposition in
manganism but recent evidence suggests that Mn deposi-
tion may also occur in substantia nigra [47–49]. Substantia
nigra is a specific brain region concerned with dopamine
production. The progressive loss of dopaminergic neurons
on manganese accumulation in this region is responsible
for the pathophysiology of parkinsonism. PET neuroimaging
studies carried out on animal models chronically exposed to
Mn reported movement abnormalities in absence of nigros-
triatal neuronal degeneration through inhibition of striatal
dopamine release [50–52]. These studies revealed dysfunc-
tion of dopaminergic system in the cause of motor deficit.
However, the detailed mechanism regarding whether Mn
could have an impact on motor abnormalities in absence of
dopaminergic neurodegeneration needs to addressed using
advance molecular biology tools. The magnetic resonance
imaging (MRI) of parkinsonism patients with history of
exposure to manganese indicated the increased intensity
in globus pallidum and substantia nigra regions of brain
[53]. T1-weighted magnetic resonance imaging (MRI) and
fluorodopa positron emission tomography (PET) scans of
patients diagnosed with idiopathic parkinsonism, including
the career welders, were carried out [54]. The results of the
scans were found to be typical of idiopathic parkinsonism
and were similar for both welder and nonwelder populations.
Moreover the 6-(18F) fluorodopa PET scan of 43-year-old
female parkinsonism patient was found to be abnormal while
T1-weighted magnetic resonance imaging (MRI) of internal
segment of the globus pallidum displayed increased signal
[55]. These studies concluded that the manganese induced
parkinsonism and Parkinson’s disease share similar clinical
and pathophysiological features.
3. Oxidative Stress Mechanism in
Manganese Neurotoxicity
Manganese induced oxidative stress is known to cause
dopaminergic cell death via apoptosis (Figure 2). The trans-
port of manganese to cellular system occurs by simple
diffusion processes. Other factors like diet such as body
iron status may also determine the absorption of manganese
[56, 57]. There is an inverse relationship between the body
iron status and manganese uptake since both compete for
the same transport machineries such as transferrin/divalent
metal transporter-1 (DMT1) [34, 57]. Various in vivo and in
vitro cell models (representing central nervous system and
brain) have been used to gain the mechanistic insight of
manganese neurotoxicity. All these studies have identified
the common signaling molecules such as PKC𝛿 that leads to
apoptosis in these cellular systems [58]. Upon entering the
cell Mn may have three cellular targets as shown in Figure 2.
It may induce the endoplasmic reticulum stress and/or can
accumulate in mitochondria and/or can cause the dopamine
autooxidation. Mitochondria are an important cellular target
in manganese neurotoxicity. Mitochondrial accumulation of
manganese results in the inhibition of oxidative phospho-
rylation and generation of reactive oxygen species (ROS)
[59]. Mn was found to interact with complex I and/or
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Figure 1: The specific regions of the brain influenced via manganese exposure depending on the level and potential of exposure. Globus
pallidus is amajor part of basal ganglia region of brain that includes substantia nigra. Dopamine is an important neurotransmitter, produced in
the brainmainly by dopaminergic neurons in substantia nigra.The progressive loss of dopaminergic neurons due tomanganese accumulation
in substantia nigra over the prolonged exposure period leads to development of parkinsonism. Manganism happens on high acute exposure
and accumulation of manganese, specifically in the globus pallidus.
complex II and F1ATPase and may also interfere with Ca2+
activated ATP production uponmitochondrial accumulation
(Figure 2) [60–62].The intramitochondrial Ca2+ regulates the
rate of ATP production via binding a series of Ca2+-sensitive
sites. Ca2+ activated dehydrogenases are associated with the
Krebs cycle such as pyruvate dehydrogenase (PDH), isoci-
trate dehydrogenase (ICDH), 𝛼-ketoglutarate dehydrogenase
(𝛼KGDH), and F1F0 ATP synthase [63]. Mitochondrial
accumulation of manganese was found to interfere with the
Ca2+ activated ATP production through binding with Ca2+-
sensitive sites inmitochondrialmetabolic enzymeswithmore
affinity than that of Ca2+ itself [64]. ATP is an important
paracrine signaling molecule mediating the intracellular
communication between the astrocytes through transmission
of Ca2+ waves. Ca2+ signaling is a critical process for regu-
lating the synaptic function, metabolism, and cerebral blood
flow in central nervous system [65]. The neurodegenerative
diseases such as Parkinson’s and Alzheimer’s diseases have
been associated with dysfunction in the Ca2+ signaling [66].
Transient receptor potential channel TRPC3 was linked with
pathophysiological activation of astrocytes [67]. Recently the
ability of manganese to affect Ca2+ signaling was studied
in striatal astrocytes and Mn was found to inhibit the
Ca2+ influx in astrocytes through receptor potential channel
TRPC3, most likely through competition for Ca2+ influx
through these cation channels (Figure 2) [68]. However,more
detailed electrophysiological studies are needed to precisely
predict the mechanism through which manganese induced
disruption of Ca2+ signaling in astrocytes.
Exposure to manganese causes the release of cytochrome
C from mitochondria followed by subsequent loss of mito-
chondrial electrical potential (Figure 2). Cytochrome C can
initiate a chain of molecular signaling events leading to
caspase-3 mediated apoptosis. Caspase-3 is a key mediator
of apoptosis and presumed to be activated downstream to
cytochrome C. Protein kinase C (PKC𝛿) has been identified
as a proximal regulator of apoptosis [58]. Critical regulation
of its cleavage and transportation to nucleus may determine
the fate of cell survival or cell death. The nuclear transport of
its activated form of cleaved product (41 kDa) makes the cell
irreversibly committed to apoptosis. The proapoptotic PKC𝛿
(74 kDa) is reported as a downstream substrate for caspase-
3 released from mitochondria as a result of mitochondrial
damage (Figure 2). Caspase-3 cleaves the PKC𝛿 (74 kDa) to its
proteolytic active product PKC𝛿 (41 kDa) that can translocate
to nucleus and may cause the expression of proapoptotic
genes [58, 69]. Activation of PKC𝛿 has been identified as a
key event in the dopaminergic degeneration in animal PD
models and apoptotic cell death of dopaminergic neuronal
cells (N27) exposed to 6-hydroxydopamine (6-OHDA) [70].
Oxidative stress induced mitochondrial dysfunction upon 6-
OHDA exposure followed by release of caspase-3 considered
to be responsible for proteolytic activation of PKC𝛿 [70].
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Figure 2: Schematic summarizing the oxidative stress mediated apoptotic pathway through which manganese causes the dopaminergic cell
death and is involved in neurotoxic effects.Mn enters neuronal cells via transferrin/DMT1 receptor. Inside cell,Mnprimarily gets accumulated
in mitochondria causing inhibition of complex I/II and F1ATPase and interferes with Ca2+ activated ATP production. This resulted in loss
of mitochondrial potential with release of Cyt C. Mitochondrial dysfunction also causes the generation of oxidative stress (ROS/RNS). The
oxidative stress resulting from dopamine autooxidation causes damage to DNA/RNA/protein/lipid and releases inflammatory mediators that
activate ERK/MAPK pathway. Activated kinase phosphorylates FoxO, preventing its translocation to nucleus and activation of antioxidant
enzyme genes. Mn may also cause the endoplasmic reticulum (ER) stress that resulted in activation of caspase-12 through unfolded protein
response. Caspase-12 may further activate the other downstream multiple caspases which culminates in apoptotic cell death. Cyt C released
upon mitochondrial damage activates caspase-3, a critical regulator of apoptosis. Caspase-3 proteolytically activates the protein kinase C 𝛿
(PKC𝛿) that again can activate ERK/MAPK pathway or on translocation to nucleus causes the expression of proapoptotic genes, resulting in
mitochondrial mediated apoptotic cell death. Protein phosphatase 2A is a downstream substrate for PKC𝛿; activation of PP2A reduces the
activity of tyrosine hydroxylase, inhibiting the dopamine production.
Protein phosphatase 2A (PP2A) is known to regulate
the activity of tyrosine hydroxylase (TH) enzyme which
is responsible for dopamine synthesis [71]. Recently both
TH and PP2A were found to interact and colocalize with
PKC𝛿. PKC𝛿 may then phosphorylate PP2A to enhance
its phosphatase activity. Increased PP2A activity dephos-
phorylates TH-ser40 that reduces its enzymatic activity,
thereby depleting dopamine in nitrostriatal neurons as a
result of manganese exposure (Figure 2) [71]. The dopamine
depletion is dependent on the concentration and duration
of manganese exposure [72]. Recently zebrafish model of
manganism was reported to decrease tyrosine hydroxylase
in catecholaminergic nuclei of Mn exposed zebrafish larvae
[73]. These results are in agreement with previous in vitro
studies. There has been a functional biphasic variation in TH
activity depending on chronic or acute level of Mn exposure.
Chronic exposure leads to decrease in TH activity while acute
exposure causes increase in the TH activity. The biphasic
variation in TH activity has also been reported in human
Mn studies. Although the cause of biphasic variation is not
known, it may be hypothesized to be related to U shaped rela-
tions underlying deficiency and toxicity conditions, governed
by dose and duration of exposure. Animal models may be
used to investigate the detailed mechanism responsible for
the cause of biphasic variation in TH activity. Inhibiting the
PKC𝛿 function was found to restore TH and PP2A activities
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to normal, suggesting involvement of PKC𝛿-PP2A signaling
pathway in manganese induced reduction in TH activity
[74, 75]. Manganese ions are required for PP2A phosphatase
activity [76].The release ofMn fromPP2A active site by PP2A
specific methylesterase leads to its inactivation.
Manganese has been reported to alter the catabolism of
dopamine in dopaminergic cells [42, 77]. This causes the
autooxidation of dopamine, contributing to the generation
of reactive oxygen/nitrogen species ROS/RNS (Figure 2) [77,
78]. Free radicals cause structural and functional modifica-
tions of proteinsDNAandRNAalongwith lipid peroxidation
(F2-isoprostanes) [62, 79, 80]. Generation of free radicals
causes release of inflammatory mediators like prostaglandin
contributing to apoptotic cell death [81–83]. The pathways
that resulted in oxidative stress, inflammation, and apoptosis
uponMn exposure are linkedwith each other and are respon-
sible for the pathophysiology of neurodegenerative diseases
[84]. MAPK kinase (ERK, JNK, and p38 MAPK) regulates
a variety of cellular processes such as differentiation, pro-
liferation, and inflammatory response by acting as connect-
ing link between the extracellular signals and intracellular
signaling pathway through intermediate signaling molecules
[85]. ROS generated as a result of mitochondrial respiratory
dysfunction on manganese exposure has been reported to
trigger the activation of ERK and p38-MAPK analogous to
that of ultraviolet radiation induced ROS generation and
MAPK activation (Figure 2) [86–88]. Dopamine producing
cells exposed tomanganese has been reported to cause reduc-
tion in glutathione and glutathione peroxidase synthesis, an
important antioxidant in cellular defense against oxidative
stress [3, 68, 89]. SHSY5Y cells exposed to manganese were
reported to cause oxidative DNA damage. These cells were
found to be rescuedwhen supplementedwith antioxidantsN-
acetyl cysteine and glutathione.This suggests the involvement
of ROS and depletion of antioxidants in apoptotic cell death.
Expression of antioxidant genes is tightly regulated inside the
cell. A forkhead box transcription factor class O (FoxO) is a
critical transcriptional factor that regulates these antioxidant
genes [90]. Phosphorylation and dephosphorylation events
of FoxO decide the fate of its activity. Dephosphorylated
form is located in nucleus where it mediates the transcription
of antioxidant/protective genes on manganese exposure.
Recently FoxO has been reported as one of the downstream
substrates for MAPK kinase in rat neonatal astrocyte cul-
tures (Figure 2) [90]. Increased phosphorylation of FoxO
prevents its translocation to cell nucleus, thus inhibiting the
transcription of antioxidant genes contributing as one of
the factors to the chain of events which results in neuronal
cell death [91]. Recently C. elegans models of manganism
have reported that the loss of glutathione S-transferase (GST-
1) associated with increased loss of dopaminergic neurons
and neurodegeneration [8]. The other downstream substrate
for PKC𝛿 mediated apoptotic cell death has not been yet
identified but it has been proposed that factors such as DNA
protein kinase (DNA-PK),MAP-kinase, scramblase, andNF-
kappa transcription factor may be involved in this process
[92–94].
Manganese exposure was found to cause endoplasmic
reticulum (ER) stress in nigral dopaminergic neuronal cells
SN4741.The ER stress results in the upregulation of unfolded
protein response genes such as BiP and activation of caspase-
12 (Figure 2) [95]. Caspase-12 subsequently activates multiple
downstream caspases (Casp-8, Casp-9, Casp-1, and Casp-3)
which leads to apoptosis in SN4741 cells. Manganese exposed
T98G cells have shown significant upregulation of caspase-
3 in proportion to that of elevated DNA fragmentation [96].
The mechanism that causes ER stress and caspase-12 medi-
ated activation ofmultiple caspases in response tomanganese
exposure is not being studied. However overexpression of
Bcl-2 in these cells has been shown to have neuroprotective
function that confirms the role of caspases in neuronal cell
death.
1-Methyl-4-phenyl-1-2-3-6-tetrahydropyridine (MPTP)
is a precursor to 1-methyl-4-phenylpyridinium (MPP+),
a known neurotoxin responsible for causing the death of
dopaminergic neurons in substantia nigra of brain and
inducing permanent symptoms of Parkinson’s disease [97].
Manganese treated PC12 cells have shown similar effects
and mode of action to that observed with MPTP exposure
[87]. Majority of in vitro studies have focused on the effect
of manganese exposure on dopaminergic system while
relatively few studies have considered nondopaminergic
system [91]. Divalent metal transporter-1 (DMT1) is major
transporter protein for manganese and is reported to be
present in inner ear cells [98, 99] although the exact cellular
location of DMT1 is still not determined. Manganese was
reported to be toxic for neurons and sensory cells in cochlear
cultures from postnatal rats suggesting that hearing deficit
may occur with excess manganese exposure [100].
3.1. Oxidative Stress Influencing Epigenetic Regulation. Recent
studies have focused on the epigenetic mechanisms that can
modify the regulation of gene expression. Epigenetic alter-
ations do not involve the change in nucleotide sequence but
rather influence the process that governs gene expression.The
epigenetic processes that have been recognized to regulate
gene expression are DNAmethylation and histone modifica-
tion along with miRNAs that act at posttranscriptional level.
DNA methylation in conjugation with histone modification
controls the accessibility of transcription factors to promoter
region of genes. There is growing evidence suggesting the
implication of epigenetic mechanisms in susceptibility and
progression of environmental toxicants induced diseases
[101, 102]. Epigenetic mechanism has been also reported to
be responsible for causing various neurological disorders
[15]. Upon manganese exposure, oxidative stress mediated
apoptotic cell death has been well recognized mechanism for
neuronal cell death. Generation of oxidative stress and its
influence on epigenetic regulation have been investigated in
several in vitro and in vivomodels but not in the context with
manganese induced neurotoxicity.
Exposure to various heavy metals including As, Pb,
Cd, and Ni has been reported to alter DNA methylation
levels [103]. Heavy metal exposure generates reactive oxygen
species through redox cycling [104]. Inhibition of antioxidant
defense systemmay further potentiate ROS induced oxidative
damage as reported and already discussed in relevance to
manganese exposure in the previous section. The DNA
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lesions such as base modifications, deletions, and chromo-
some rearrangements caused by oxidative stressmay interfere
with ability of DNA methyltransferase to use DNA as a
substrate, altering the global or gene specific methylation
[105–107]. Alternations in DNA methylation mostly occur
at CpG sites situated at the promoter region of genes.
Methyl group in 5-methylcytosine has role in binding to
transcriptional factors and transcriptional repressor methyl-
CpG binding protein 2 (MeCP2) in sequence specific DNA
protein interactions [108–110]. DNAmethylation at CpG sites
either prevents binding of transcription activators or recruits
the transcriptional repressor (MeCP2) that may alter gene
expression by interacting with histone deacetylase (HDAC).
DNA methylation in association with histone deacetylase
mediates repression of gene expression by generating the
heterochromatin regions that result in potential heritable
epigenetic alterations. 5-Methylcytosine is prone to oxi-
dation and hydroxymethylcytosine is formed as a result
of methylation. This reverses the binding of MeCP2 and
further steps in chromatin condensation and silencing of
gene expression [111]. ROS induced oxidative DNA damage
leads to the global hypomethylation at CpG sites [112]. The
global DNA methylation level was found to be increased
in BEAS-2B cell exposed to 150𝜇M H
2
O
2
for 3 days [113].
Additionally, BEAS-2B cells chronically exposed to arsenic
were reported to induce ROS and promote tumorigenesis
via downregulation of miR-199a-5p [114]. HIF-1𝛼 and COX-
2 are identified as the downstream targets of miR-199a-5p
[113]. The activation of HIF-1𝛼 via epigenetic mechanism
was found to be associated with the occurrence of several
types of cancer [115, 116]. Hypermethylation of glutathione-
S-transferase P1 (GSTP1) gene was reported in intraepithelial
neoplasia (HG-PIN) that makes the cells more susceptible to
oxidative stress mediated DNA damage [117]. Gene specific
promoter methylation in response to oxidative stress has
been reported in the tumor suppressor gene RUNX3 [107,
118]. Methylation of E-cadherin promoter was reported in
human colorectal and hepatocellular carcinoma cells [119].
Methyl-CpG binding protein 2 (MeCP2) is key contributor
in epigenetic silencing of genes. MeCP2 gene mutation has
been reported to cause neurodevelopmental disorder (Rett
syndrome) [107]. The MeCP2 gene promoters have been
found to be heavily hypermethylated in neuronal tissues.
These results were confirmed by chromatin immunoprecip-
itation with anti-MeCP2 antibody in mice neuronal tissue
cells [120]. The reactive oxygen species (ROS) generated as
a result of iron sulfate or aluminum sulfate exposure have
been reported to cause the upregulation of miRNAs, such as
miR-9, miR-125b, and miR-128, in in vitro cell models [121].
Histone methylations primarily, histone H3 and histone H4,
were among the important epigenetic modifications [122].
Recently, oxidative stress generated through occupational
exposure to arsenic was reported to increase H3K4me2
leading to transcriptionally active euchromatin regions [123].
This suggests the influence of oxidative stress on epigenetic
regulation in cells. The histone deacetylase such as HDAC3
was found to be susceptible to oxidative damage. Thus
oxidative stress mediated loss of activity may affect the global
histone deacetylation [80]. Recent studies in context with
alteration of epigenetic mechanism in response to environ-
mental toxicants entail the contribution of oxidative stress as
probable factor in mediating epigenetic changes [123].
These studies firmly confirm the ability of oxidative stress
to deregulate the epigenetic mechanism of gene regulation.
Oxidative stress mediated mechanism has been well estab-
lished in manganese induced neurotoxicity; however the
potential involvement of epigenetic deregulation has not been
addressed. Studies involving the impact of Mn exposure on
epigenetic regulation are not available. Hence at present,
in-depth investigation is required on the oxidative stress
mediated epigenetic alteration upon manganese exposure.
Thiswill facilitate better understanding of the potential role of
epigenetic mechanism in manganese induced neurotoxicity.
4. Epigenetics of Parkinson’s Disease
Parkinson’s disease (PD) is amongst the common and well
known neurodegenerative diseases mostly characterized by
the presence of Lewy bodies in dopaminergic neuronal cells.
PD is described as the idiopathic syndrome of parkinsonism.
However, studies have correlated the occurrence of PD with
the inheritance of defective genetic signatures [124, 125].
Generation of oxidative stress, mitochondrial dysfunction
leading to energy imbalance, and defective ubiquitin medi-
ated proteasomal cellular pathways has been identified to
be responsible for PD [126]. A recent study entails that
environmental pollutant induced epigenetic modifications
are capable of bringing the perturbation to gene expression
as similar to that observed with pathogenic gene mutations
in PD [92]. Long term chronic exposure to certain metals
like copper and manganese individually or in combination
has been significantly found to be connected with increased
risk of Parkinson’s disease [9, 127]. At cellular level PD is
often characterized by eosinophilic Lewy bodies in dopamin-
ergic neurons of substantia nigra of the brain consisting of
aggregates of normal and misfolded proteins [128]. Recently,
mutation in parkin gene was reported in PD patients of
south India, without the development of Lewy bodies [129].
Clinical symptoms of PD are observed through progressive
loss of dopaminergic neurons followed by reduced secretion
of dopamine [130]. Mn exposure causes reduced secretion
of dopamine through PKC𝛿-PP2A signaling via inhibiting
the TH activity. This finding supports the definitive role
of environmental Mn exposure in etiology of PD. How-
ever review paper by Guilarte raises controversy against
the similarities between manganese induced parkinsonism
and idiopathic Parkinson’s disease [131]. The hypothesis of
the review was based on the studies performed on IPD
patients to their response to levodopa therapy at different
time period during the course of disease. Hence direct
correlation between manganese induced parkinsonism and
IPDmay be problematic. Familial cases of PD associated with
genetic mutation in SNCA, parkin, UCHL-1, PINK1, DJ1,
and LRKK2 genes contribute only 5–10% of PD cases while
the majority of PD cases are idiopathic [132, 133]. Recessive
mutation to other PD linked genes such as parkin/PARK2
and DJ1 leads to loss of their functions and is reported to
be responsible for early onset of parkinsonism [134]. Parkin
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is E3 ubiquitin ligase that regulates protein functions via
targeting them for proteasomal degradation [134]. Figure 3
entails the molecular (genetic/epigenetic) events involved
during the development of PD. Divalent metal transporter
DMT1 has broad specificity for transport of metal ions but
plays a significant role in transport of manganese [135, 136].
DMT1 is a substrate for parkin and hence is involved in
maintaining steady state level of this transporter [137]. Loss of
parkin function makes the cell susceptible to elevated uptake
of manganese [138]. DJ1 function is an oxidative stress sensor
in neuronal cells of brain. The inactive oxidized form of DJ1
was found to be elevated in sporadic PD brain patients [139].
Inactivation of DJ1 can make the cell more vulnerable to
the oxidative stress induced neuronal cell death (Figure 3)
[140]. Simultaneous miRNA analysis in differentiated SH-
SY5Y cell line and PD brain samples revealed depletion or
reduction inmiR-34b/c [141, 142]. Further, this reduction was
found to be associated with reduced parkin and DJ1 protein
expression [143]. This suggests the adverse effect of man-
ganese exposure on epigenetic mechanism. Dysregulation in
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parkin and DJ1 function makes the cell prone to oxidative
stress and mitochondrial dysfunction that compromises cell
viability as shown in Figure 3 [144, 145]. However, the
components of mitochondrial proteins that are modulated by
miR-34b/c disruption need to be identified. Related studies
have demonstrated that overexpressing parkin and PD linked
genes can eliminate the 𝛼-syn induced neurotoxicity. It was
found that E3-ligase activity of parkin is responsible for
degradation of 𝛼-syn [146]. The release of cytochrome C
from mitochondria as a result of mitochondrial membrane
disruption is crucial for initiation of apoptosis. Recently
parkin has been reported to inversely affect the release of
cytochrome C and mitochondrial function in SH-SY5Y cells
along with murine and fly models of parkin deficiency [145,
147, 148].
Alpha-synuclein (𝛼-syn) is small soluble protein (14 kDa)
expressed primarily at presynaptic terminals and is natively
unfolded, although it gets folded when associated with
membrane and when binding lipid molecules [149, 150]. 𝛼-
syn has gathered considerablymuch interest in recent years as
alteration in its gene expression was reported to be involved
in the cause of several neurodegenerative diseases including
Parkinson’s disease [151, 152]. In vitro investigations have
revealed that 𝛼-syn is a major component of Lewy bodies
consisting of aggregates of𝛼-syn protofibril formed as a result
of excessive oxidative stress generated through autooxidation
of neurotransmitter dopamine [153–155]. Alpha-synuclein
overexpression can significantly contribute to the increased
risk of sporadic PD [156, 157]. PD patient’s brain samples have
shown the hypomethylation of SNCA intron 1 correlating
with an increased expression of 𝛼-syn (Figure 3) [158–162].
Apart from DNA methylation, miRNAs were also reported
to regulate the 𝛼-syn expression at posttranscriptional level.
Specifically miR-7 and miR-153 were reported to regulate 𝛼-
syn expression in worm C. elegans and PD patients brains
(Figure 3) [163, 164]. Additionally, impairment in miR-64,
miR-55, let-7, miR-10a, miR-10b, miR-132, miR-7, miR-153,
andmiR-435 expressions in symptomatic transgenic PDmice
and PD disease models was found to be linked with increased
𝛼-syn level [163, 165–167]. FGF20 is a member of fibroblast
growth factor family that regulates the development and
function of central nervous system. Variation in miR-433
binding site of FGF20 resulted in overexpression of FGF20
[168]. Elevated FGF20 may be linked with increased 𝛼-syn
expression in PD patient brain (Figure 3) [169].
5. Implication of Epigenetic Mechanism in
Manganese Induced Parkinson’s Disease
𝛼-Synuclein has been known to play a significant role in
the dopaminergic cell death as observed in Lewy body
diseases such as Parkinson’s disease [170, 171].Themanganese
exposure generates the oxidative stress and causes dopamine
oxidation. Oxidative stress was also considered as a critical
mediator of dopaminergic cell death in Parkinson’s disease
[172, 173]. Exposure to manganese has been reported to cause
overexpression of 𝛼-synuclein in neuroblastoma cells (SH-
SY5Y) and implicated to be involved in neuronal apoptosis
(Figure 3) [18, 174]. However, the upstream mechanism lead-
ing to 𝛼-synuclein overexpression in cells exposed to man-
ganese is still unexplored. A recent finding has demonstrated
the involvement of ERK1/ERK2 MAPK pathway responsible
for 𝛼-synuclein overexpression in PC12 cells exposed to
manganese as shown in Figure 3 [17]. Hypomethylation of
𝛼-synuclein gene promoter has been demonstrated to cause
overexpression of 𝛼-synuclein in PD and related disorder
[162]. Thus it may be hypothesized that alterations in methy-
lation pattern may be responsible for manganese induced 𝛼-
synuclein overexpression.
Overexpression of 𝛼-synuclein may lead to the onset of
apoptosis (Figure 3). Oxidative stress and neurotransmitter
dopamine may contribute to the 𝛼-synuclein aggregation in
in vitromodels. 𝛼-Synuclein aggregationmay further damage
dopaminergic neurons in worm C. elegans [151, 175, 176]. 𝛼-
Synuclein aggregation was reported to impair the biosyn-
thetic pathway for dopamine transporter biosynthesis and
subsequent maturation and trafficking (Figure 3) [177]. 𝛼-
syn may form the oligomers under the influence of oxidative
stress that may lead to the fragmentation of Golgi complex
[177].
𝛼-Synuclein has been recognized to play dual role in
neuronal cell. When expressed at normal physiological level
𝛼-synuclein is neuroprotective while overexpression beyond
a certain threshold level resulted in toxicity (Figure 3) [178].
The nuclear localization of 𝛼-synuclein was reported to cause
the downregulation of proapoptotic PKC𝛿 (Figure 3) [179].
Oxidative stress was identified to be responsible for the
nuclear translocation of 𝛼-synuclein in dopaminergic cells
[180]. Nuclear translocation of𝛼-synuclein has been shown to
cause increased susceptibility to oxidative stress in MES23.5
cells [173]. NF-𝜅B and p300 were designated as vital nuclear
proteins, involved in the modulation of PKC𝛿 expression
in dopaminergic neurons of 𝛼-synuclein transgenic mice
[181]. Expression of 𝛼-synuclein at normal level protected
neuronal cells against 1-methyl-4-phenylpyridinium (MPP+)
or rotenone toxicity [182]. Recent in vivo and in vitro studies
provide evidence that 𝛼-synuclein interacts with histone
proteins (p300) and reduces its histone acetyltransferase
activity. Subsequent activation of p65 suppresses the bind-
ing of general transcription machinery (GTM) to PKC𝛿
promoter and represses its gene expression (Figure 3) [179,
181, 183]. PKC𝛿 is an oxidative stress kinase and a critical
regulator of apoptosis in central nervous system, recognized
as downstream substrate for caspase-3. Proteolytic activation
of PKC𝛿 was reported to be involved in the dopaminergic
cell death in cellular models of Parkinson’s disease [184–186].
The mechanism through which 𝛼-synuclein interacts with
and disrupts p300 acetyltransferase activity is not yet clear.
However, administration ofHDAC inhibitors was reported to
restore the acetylation state and protect neuronal cells against
𝛼-synuclein toxicity [187, 188]. In another prime study, it
was reported that overexpressed soluble 𝛼-synuclein forms a
complex with antiapoptotic 14-3-3 protein in 54–83-kD com-
plex that makes neuronal cell vulnerable to mitochondrial
apoptotic cell death (Figure 3) [155, 189].
Recent studies with human postpartum brain sample of
PD patients and 𝛼-synuclein transgenic mice models have
10 BioMed Research International
Mn Generation of 
ROS/RNS 
(oxidative stress)
Epigenetic 
deregulation
Loss of epigenetic
Acts epigenetically
𝛼-Synuclein
overexpression
Cytoplasm Nucleus
Interacts with histone
protein p300
Global hypomethylation, including
PD associated genes: SNCA, PARK2, 
Reduces histone acetyltransferase
(HAT) activity, regulating 
expression at promoter
regulator of apoptosis
Hypomethylation of 
SNCA promoter
Downregulation of 
miR-7/miR-153
Sequestration of DNA 
methyltransferase 
1 (DNMT1)
regulation of 𝛼-synuclein
epigenetically; PKC𝛿, critical
PKC𝛿
and PARK7
Figure 4: Schematic representing probable involvement of epigenetic deregulation caused by the overexpression of 𝛼-synuclein in in vitro
and in in vivo cell models of Parkinson’s disease.The oxidative stress resulting fromMn exposure has a potential to alter epigenetic regulation
of 𝛼-synuclein via hypomethylation of SNCA gene promoter or through downregulation of miR-7/miR-153. Overexpressed 𝛼-synuclein acts
epigenetically via sequestration of DNA methyltransferase in cytoplasm. This causes the global change in DNA methylation profile of genes
associatedwith PD.𝛼-Synuclein inside nucleus regulates the expression of PKC𝛿 epigenetically, a proximal regulator of apoptosis.𝛼-Synuclein
inhibits binding of protein transcriptional machinery to PKC𝛿 gene promoter region via binding histone protein p300 and inhibiting its
histone acetyltransferase activity.
reported the association between DNA methyltransferase
(DNMT1) and 𝛼-synuclein, resulting in aberrant cytoplasmic
localization of DNMT1 (Figure 4) [155, 189, 190]. Interaction
of 𝛼-synuclein with histone proteins and inhibition of its
acetyltransferase activity suggest the direct role of histone
proteins in epigenetic regulation (Figure 4).
The sequestration of DNMT1 in cytoplasm results in
global DNA hypomethylation including PD associated genes
such as SNCA, SEPW1, and PRKAR2A in both human and
mice brain samples (Figure 4) [190]. Epigenetic mechanism
including DNA methylation regulates the neuronal develop-
ment and environmental factors were reported to interfere
with the regulatory processes at epigenetic level [191, 192].
Developmental manganese exposure in mice was reported
to affect neurogenesis in hippocampal dentate gyrus [193].
Global DNA methylation microarray profiling of hippocam-
pal dentate gyrus following manganese exposure revealed
hypermethylation of several genes involved in differentiation
processes [194]. These findings suggest that deregulation of
epigenetic mechanism could be a potential mediator that
affects the hippocampal neurogenesis in response to the
exposure to manganese. Chronic exposure to manganese has
been reported to result in Parkinson’s disease in both in vivo
and in vitro cell models. In recent years, environmental epige-
netic research has grown very rapidly. Various environmental
pollutant induced diseases have been linked with disruption
of epigenetic regulation. Manganese exposure could result in
neuronal toxicity and neurodegenerative diseases. However,
role of manganese induced epigenetic variation in context of
neurodegenerative diseases needs to be further investigated.
This will help us to develop suitable and effective prognostic
and therapeutic approaches.
6. Genetic Polymorphism in Epigenetic
Susceptibility to Manganese Neurotoxicity
Variation in DNA sequences, epigenetic mechanism, and
environmental factors may act synergistically to contribute
to the development of neuronal disorders. DNAmethyltrans-
ferase (DNMT1) maintains the methylation pattern through
generations, whereas the de novo DNMT (DNMT3A,
DNMT3B) introduces the tissue specific methylation marks
during the development or in response to environmental fac-
tors. Genetic polymorphism in DNMT could be the critical
event in epigenetic susceptibility to environmentally induced
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chronic disease. Recently, a south Indian population was
studied for genetic polymorphism in DNMT1, DNMT3A,
DNMT3B, and DNMT3L for association with schizophrenia.
The genetic variants in DNMT1, rs2114724 and rs2228611,
were found to be significantly associated with schizophre-
nia while de novo DNMTs variants, DNMT3B rs2424932,
DNMT3B rs156968, and DNMT3L rs2070565, were associ-
ated with early age onset of disease [195]. This study had
demonstrated the role of genetic polymorphism in DNA
methyltransferase and its association with individual methy-
lation level and susceptibility.However, the studies pertaining
to the identification of genetic susceptibility factors have been
limited and invariantly inconsistent [195].The individual dif-
ferences at genetic level determine the response of individual
to different environmental stimuli. These differences can be
attributed to the variability in response of individuals, even
experiencing a similar level of exposure. Epidemiological
studies in recent years have reported the positive correlation
between the single nucleotide polymorphisms (SNPs) in
genes involved in manganese detoxification and differences
in individual’s susceptibility to manganism [196, 197]. The
differences in individual genotypes might be responsible
for the variability in blood manganese level of manganese
miners experiencing the same exposure environment. It is
evident that merely evaluating the blood manganese level in
exposed populationwith individual genotypic differencemay
not predict the subjects who are more prone to manganese
related neurological diseases. In agreement with the above
findings, recently research group at our lab have studied the
genetic polymorphism in cytochrome P450s, glutathione-S-
transferases and NAD(P)H, and quinone oxidoreductase in
manganese miners of central Indian population [198]. The
finding suggests the association between the cytochrome
P450 CYP2D6 polymorphism and susceptibility to chronic
manganism [198]. However, the mechanism by which vari-
ant of cytochrome P450 CYP2D6 has protective role in
manganese susceptibility is not well understood. It might
be attributed to perturbation in manganese metabolism or
association with other polymorphic alleles of gene that may
increase or decrease the enzymatic activity. It is evident
from the study that cytochrome P450 CYP2D6 may be
considered as a susceptibility biomarker for identifying the
miners who are at higher risk for developing manganism.
Iron and manganese are supposed to share similar transport
and regulatory proteins. It is demonstrated that divalent
metal transporter-1 (DMT1) mediates the transport of iron
and manganese [199]. Recently, animal studies have found
the inverse relationship between the body iron stores and
absorption of manganese [34]. It was reported that defi-
ciency of iron resulted in significant increase in manganese
absorption and retention in various organs of laboratory
animals models [57]. Hepcidin is a regulatory hormone,
product of HEP gene that controls the iron absorption in
response to total body iron status [200]. The variants of
HEP genes, C282Y and H63D, have been reported to be
associated with increased uptake of dietary iron [201]. Recent
study has found that the individuals with variant of HEP
gene had 12% lower blood manganese level in comparison
to the wild-type subjects [202]. As discussed earlier that
FGF20 is a member of fibroblast growth family that regulates
the development and function of central nervous system, it
was demonstrated that variation in miR-435 binding site of
FGF20 gene, due to single nucleotide polymorphism (SNP),
resulted in the FGF20 overexpression [169]. Elevated level
of FGF20 has been linked with overexpression of 𝛼-syn,
a characteristic of Parkinson’s disease (Figure 3) [169, 196]
although the mechanistic insight of the process that leads to
𝛼-syn overexpression due to elevated FGF20 has not been
investigated. However it is evident that the perturbation of
epigenetic mechanism (miRNA binding site alteration in
FGF20 gene) might be involved in manganese mediated
overexpression of 𝛼-syn, implicated in the development of
Parkinson’s disease. It may be suggested that the individuals
in population having SNP in FGF20 may have altered epige-
netic regulation of 𝛼-syn. Hence these individuals might be
predicted at higher risk of developing parkinsonism or other
neurodegenerative disorders in response to environment or
occupational manganese exposure. Epidemiological studies
suggest the definitive link between the genetic polymorphism
and epigenetic susceptibility tomanganese neurotoxicity.The
more comprehensive molecular approaches might give in-
depth understanding of the individual genetic differences
to association with epigenetic susceptibility in relevance to
manganese exposure.
7. Conclusion
Epigenetic signatures influenced by manganese exposure
need to be studied to gain better understanding of the
molecular pathway leading to neuronal cell death and its
implication in Parkinson’s disease. Most of the findings and
interpretation on the mechanism of manganese induced
neurotoxicity are based on the high exposure levels of
manganese in experimental models, which is considered to
induce manganism in humans. This exposure level should
not be correlated with chronic low level lifetime exposure in
humans. Further studies are needed to investigate whether
the molecular pathways that are responsible for manganese
induced dopaminergic cell death in humans are similar to
those reported in scientific studies using in vivo/in vitro cell
models. The single nucleotide polymorphism in genes deter-
mines the susceptibility level of an individual in response
to toxicant exposure. How the epigenetics is linked with
genetic susceptibility might be the exciting area of research
to be investigated in future. The study of epigenetic mech-
anism may further elaborate the present knowledge about
manganese neurotoxicity. The definitive pathways may be
identified which can be used as target for disease progression
and therapeutics in relevance to manganese exposure.
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